Treatments and Prognosis for Subchondral Cystic Lesions in the Distal Extremities in Thoroughbred Prospect Racehorses.
Authors: Pérez-Nogués Marcos, López-Sanromán Javier, Spirito Michael, Manso-Díaz Gabriel
Journal: Animals : an open access journal from MDPI
Summary
# Editorial Summary Subchondral cystic lesions (SCLs) affecting the fetlock and interphalangeal joints represent a significant challenge in young Thoroughbreds, yet evidence comparing treatment approaches has been limited to lesions in the stifle. This retrospective analysis examined 113 yearlings treated between 2014 and 2020 for distal extremity SCLs using four different interventions—intralesional corticosteroid injection, transcortical drilling, cortical screw placement, and hydroxyapatite implant placement—against 109 unaffected maternal siblings to evaluate both athletic prognosis and economic impact. Whilst treated horses achieved similar race-starting ability compared to controls (60.2% versus 69.7%), their auction values were substantially depressed, and larger SCL heights correlated with reduced numbers of wins and placed races; notably, neither treatment type nor the specific bone affected demonstrated any meaningful difference in racing performance outcomes. For equine professionals managing yearlings with distal extremity SCLs, these findings suggest that treatment selection may be driven more by case-specific factors and clinician preference rather than evidence of superior outcomes, though lesion size warrants consideration in prognosis discussions and economic counselling with owners should acknowledge persistent performance expectations despite surgical intervention.
Read the full abstract on PubMed
Practical Takeaways
- •SCLs in distal extremities carry a financial penalty at sale regardless of treatment chosen—expect lower auction values for yearlings with these lesions
- •Treatment selection should not be based on hopes for improved racing performance, as all four methods produced equivalent outcomes; choose based on individual case characteristics and practitioner preference
- •Larger SCLs (by height) predict worse racing outcomes; counsel owners that bigger lesions correlate with fewer wins, even after treatment
Key Findings
- •No significant difference in race-starting ability between treated SCL cases (60.2%) and unaffected siblings (69.7%)
- •Treated horses had significantly lower auction values compared to unaffected siblings
- •SCL height negatively correlated with number of wins and placed races, independent of treatment type
- •Treatment type (corticosteroid injection, transcortical drilling, cortical screw, hydroxyapatite implant) did not affect racing performance outcomes or sale price